INTRODUCTION
Microarrays provide a method for measuring the relative abundance of mRNA transcripts found in a sample of cells (1) . This allows expression levels between, for example, different cell lines, treatments, or tissue types to be compared. Previous work has drawn attention to the need to carefully control the processes used to extract, purify, and prepare RNA for hybridization to microarrays (2) because variations in protocols can have significant effects on the variation seen between specific samples (3) . Consequently, it is common for laboratories to standardize a specific protocol, which is followed meticulously, and even for groups to agree to use the same set of protocols whenever possible. In addition, standards such as the minimum information about a microarray experiment (MIAME) (4) have been developed to ensure that experimental annotation provides a robust and rigorous description of the techniques used for RNA handling.
One issue with microarray experiments is that a relatively large amount of starting material is required for hybridization. The Affymetrix standard protocol (http://bioinformatics.picr.man. ac.uk/mbcf/protocols.shtml) (Affymetrix, Santa Clara, CA, USA), for example, requires between 5-10 μg total RNA, from which biotinylated cRNA is synthesized via in vitro transcription. This corresponds to about 10 6 -10 7 cells from cell culture or 70-700 μg of wet tissue weight (5, 6) , but depends very much on the origin of the biological sample. As a result, it has not been possible to use microarrays to study gene expression profiles from small sample biopsies (7), fine-needle aspirates (which yield approximately 1 μg total RNA) (2, 8) , or cells taken from heterogeneous tissues sampled by laser capture (9, 10) . For this reason, considerable effort has been directed at developing protocols that allow the technology to be used with much smaller amounts of starting material, and several protocols and kits [from such manufacturers as Affymetrix, Ambion (Austin, TX, USA), Arcturus Bioscience (Mountain View, CA, USA), and Roche Applied Science (Indianapolis, IN, USA)] are now available for researchers working with nanogram quantities of RNA (9, (11) (12) (13) (14) (15) (16) . In this paper, we evaluate one such protocol-the Affymetrix small sample protocol-designed to be used with between 10-100 ng total RNA and compare its results to that of the Affymetrix standard protocol.
As we shall see, the techniques used to prepare mRNA for Affymetrix microarrays require the production of a larger population of cRNA. It is reasonable to expect that this process results in systematic differences in the relative abundance of cRNAs and their parent mRNAs, and that different protocols will behave differently. For this reason, any comparison of protocols must consider both these systematic effects as well as the random noise introduced by the different techniques. Several other studies have focused on the reproducibility between replicate hybridizations of RNA processed with or without a round of amplification (7, 10, 16) , the effects of increasing the number of rounds of amplification (17, 18) , and with samples captured by microdissection (9,10). Here we consider the effect of the protocol on an entire experiment (rather than only looking at technical replicates from the same RNA sample) because this allows both systematic and random errors to be examined.
The experiment investigated the differences in gene expression between a pair of cell lines. Cell lines were chosen to ensure that high-quality RNA was available, minimizing other issues that could arise during the extraction and amplification of RNA from small samples. Effectively, the only variables in the experiment are the amplification protocol and the amount of starting material; any similarities or differences observed between experiments occur solely as a result of amplification.
In addition, we consider the analysis techniques needed to interpret data produced by these two protocols, within and between Affymetrix experiments. Data analysis techniques can have a significant impact on the apparent reproducibility of an experiment, and we show that while systematic errors are present, with the appropriate strategies, they can be minimized. Nevertheless, their existence has major consequences for the design and implementation of microarray experiments.
The Standard and Small Sample Protocols
The GeneChip ® Eukaryotic Small Sample Target Labeling Assay Version II (http://www.affymetrix.com/ support/technical/technotes/smallv2_ technote.pdf; hereafter referred to as the small sample protocol) is based on the amplified antisense RNA procedure (13, 17) and is preferred to a PCR-based approach (19) , perhaps because the technique is considered by many to be more linear and produces an amplified sample that better reflects the original mRNA population (6) . With PCR-based approaches, the exponential nature of the reaction results in high levels of amplification; however, any biases (such as amplification efficiency or Taq DNA polymerase errors) are also amplified in an exponential manner. There are also issues associated with the amplified antisense procedure. It is likely, for example, that the amplification products are not full length, resulting in a population containing sequences that are 3′ biased. This arises because total RNA is used as a starting material, and the use of a reverse transcriptase primer that recognizes the poly(A) tail of mRNA generates cDNAs starting from the 3′ end of the mRNA. The cDNAs are then used as templates for the antisense in vitro transcription step, which can also introduce further biases due to possible 5′ underrepresentation and low stringency during double-stranded cDNA synthesis (12) . The fact that their probe sets are all targeted to the 3′ ends of genes suggests that biases may not be a significant issue with Affymetrix arrays;
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MATERIALS AND METHODS

Experimental Design
A simple experiment was constructed to identify genes differentially expressed between two cell lines, MCF7 (a human breast cancer cell line) and MCF10A (a human breast epithelial cell line). MCF7 was grown in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal calf serum (FCS; Invitrogen, Carslbad, CA, USA), and MCF10A was grown in DMEM/ F12 with 5% horse serum (Invitrogen), 2 ng/mL epidermal growth factor (PeproTech, Rocky Hill, NJ, USA), 0.5 μg/mL hydrocortizone, 0.5 μg/mL cholera toxin, and 5 μg/mL insulin (Sigma, St. Louis, MO, USA). RNA was extracted using TRI ® reagent (Invitrogen) followed by clean up using RNeasy ® columns (Qiagen, Valencia, CA, USA) according to the manufacturers' instructions. A single pool of RNA from each cell line was used for all dilutions and replicates shown in this study. After removing aliquots for use with the standard protocol, a set of dilution series was used to obtain aliquots containing 1, 10, and 100 ng of total RNA for each sample. The entire experiment was repeated in triplicate, yielding three samples per cell line. These were processed using the small sample protocol, and all samples were then hybridized to HG-U133A chips (Affymetrix), per the manufacturer's recommendations. Full details of these protocols can be found at http://bioinf.picr.man.ac.uk/mbcf/ protocols.shtml.
RNA Preparation Protocols
The overall strategy for the various amplification protocols that have been developed is very similar; however, the technical details vary considerably. Figure 1 shows the outline of both labeling protocols used in this study. In the standard protocol, mRNA is converted to double-stranded DNA using a twostep process. First, reverse transcriptase is used to synthesize a single-stranded DNA copy of the mRNA, and this reaction is primed using oligo(dT), which binds to the poly(A) tail of the mRNA. The oligo(dT) primer also carries the binding site for T7 RNA polymerase (both from Affymetrix). Next, the complementary strand is generated by DNA polymerase I (Affymetrix). The resultant double-stranded DNA is then able to form a suitable substrate for T7 RNA polymerase, which is used to Figure 1 . Outline of the standard and small sample protocols for generating cRNA for hybridization to GeneChips.
generate multiple copies of cRNA using the cDNA as a template, the in vitro transcription step. The ribonucleotides for this reaction are labeled with biotin, which allows subsequent detection by fluorescently labeled streptavidin. This protocol can typically generate between 40-100 μg cRNA from 10 μg total RNA (of which only about 1% is mRNA).
In essence, the small sample protocol consists of two rounds of the above, except that the cRNA synthesized in the first round is not labeled with biotin, but is instead used as the substrate for a second round of cDNA/cRNA synthesis, during which biotin-labeled ribonucleotides are incorporated. Yields are similar to those obtained with the standard protocol.
RESULTS
Quality Control and Assessment of Labeling, Amplification, and Hybridization Efficiency
Each sample was screened and found to be free from mycoplasma contamination using PCR screening (20) . Following extraction, both RNA quality and amount were verified by agarose gel. After hybridization and scanning, array images were assessed by eye to confirm scanner alignment and the absence of significant bubbles or scratches. Affymetrix includes a set of probes on the array for quality-control purposes. Some of these (labeled BioB, BioC, BioD, and CreX) are designed to recognize noneukaryotic mRNA sequences and are spiked into the labeled RNA just before hybridization, washing, and staining, which allows the efficiency of these processes to be assessed. In addition, both GAPDH and β-actin have probe sets designed to both the 3′ and 5′ ends of their sequences and to their midpoints. The ratio of the 3′ and 5′ signal gives a measure of RNA quality: a high 3′ to 5′ ratio indicates an abundance of short transcripts, which may be due to RNA degradation or problems arising during in vitro transcription.
For the 10-μg arrays, 3′ to 5′ ratios for GAPDH and β-actin were confirmed to be within acceptable limits (0.82-0.89 and 1.06-1.17, respectively). For the arrays processed using the small sample protocol, these ratios were significantly higher and increased as the amount of RNA decreased (GAPDH: 1 ng: 3.29-13.46, 10 ng: 2.75-10.84, 100 ng: 1.66-5.73; β-actin: 1 ng: 11.22-63.58, 10 ng: 6.92-28.8, 100 ng: 11.22-17.48). The effect was more pronounced for β-actin. This is to be expected, given the relative lengths of the genes (the midpoints of the 3′ and 5′ GAPDH probes are 800 kb apart; for β-actin, 1100 kb). These data strongly suggest that the amplified antisense RNA procedure does indeed produce amplification products that are not full length, with a resultant population containing sequences that are 3′ biased. Even so, GAPDH and β-actin ratios were in accord with the manufacturer's recommendations, who also suggest that the 3′/mid ratios are a better guide to RNA quality when using the small sample protocol.
BioB spike controls are designed to be present at a concentration that represents roughly three transcripts per cell, close to the detection limit of the system. They were identified as present on all of the arrays (assessed using Affymetrix MAS 5.0 array analysis software), with BioC, BioD, and CreX also present on all chips but in increasing intensity.
When scaled to a target intensity of 100 (using MAS 5.0), scaling factors for all but one of the 10-and 100-ng arrays were within an acceptable range (0.29-1.06), as were background, Q values, and mean intensities. The second MCF10A replicate amplified from 10 ng, however, was found to have a high scaling factor (1.96) combined with a small number of genes called present [in comparison with its peers (33.20% vs. 39.80%-48.60%)]. Together, these factors resulted in this chip failing quality-control procedures, and another replicate was generated (which passed quality control). Interestingly, the relationship between yield and quality-control metrics is not straightforward: MCF10A replicate 2 failed quality control but had a yield of 40 ng, but replicate 1, with a yield of 25 ng, passed quality control (yields for the MCF10A replicates were 25, 40, 41, and 39 ng, respectively). The 1-ng arrays had variable scale factors RNA TECHNOLOGIES (0.96-4.02), GAPDH (3.29-15.18), and β-actin ratios (11.22-63.58), and percentage-present calls (27.60%-41.40%). At least four of these six arrays would fail quality control, and the data in this branch of the experiment should be considered in this context. The quality-control procedures described above are heavily derived from Affymetrix guidelines, described in their Data Analysis Fundamentals manual (http://www.affymetrix.com/ support/downloads/manuals/data_ analysis_fundamentals_manual.pdf) but guided by experience (for example, Affymetrix states that 5′ to 3′ ratios should be less than 3 for unamplified samples; we rarely see ratios this high and are cautious when ratios above 2 are observed). Quality-control thresholds for amplified samples are still under development and will become more robust as more samples are processed.
Data Analysis
The raw spot readings generated by MAS 5.0 were imported into BioConductor (http://www.bioconductor.org) (21) , where expression-level summaries were generated and arrays normalized using the RMA algorithm (22) . The microarray data is MIAME compliant.
Correlations Between Replicates
Correlation within the standard sample replicates was high (approximately 0.99). As might be expected, correlation for the amplified samples was lower and reducing the amount of starting material resulted in reduced correlation between replicate arrays (100 ng, approximately 0.98; 10 ng, approximately 0.96; 1 ng, approximately 0.92); MCF10A replicate 2, which failed quality control, is marginally less correlated with its peers (approximately 0.93 vs. approximately 0.96). Arrays generated with different protocols show the weakest correlations (unamplified vs. 100 ng, approximately 0.93).
Comparison of the Results Produced Using Different Protocols
In an experiment such as this, a combination of fold change and t tests between replicate groups would typically be used to identify genes that showed significant changes in expression between the two cell lines. To investigate how changes in protocol and amount of material altered the results of the experiment, fold change and t tests were computed between the MCF7 and MCF10A cell lines for the unamplified 1, 10, and 100 ng sets. These were then filtered to generate a list of significant genes for each condition (fold change > 2.0, P score < 0.001; no multiple testing correction was applied). Because minor variations in fold change or P score can serve to include or exclude a gene from a set, attempting to compare protocols simply by comparing set membership is highly susceptible to small amounts of random noise. For this reason, we decided to investigate how similar the fold changes computed for each gene were between protocols. Figure 2a was produced by plotting the fold change generated using the unamplified samples against the fold change generated from the 10-ng replicates. Of the 2242 probe sets that were selected as significant in either set, 292 (13%) showed greater than 2-fold difference in their fold change. If we are prepared to allow a 4-fold difference Figure 2 . Effect of protocol on the fold changes calculated between MCF7 and MCF10A samples. For the 10 and 100 ng and unamplified samples, fold changes were computed between MCF7 and MCF10A replicates. (a) Crosses show the log 2 fold changes for the unamplified replicates plotted against the 10-ng samples. If both protocols were identical, this would produce a diagonal line; differences in protocol are manifested by differences in fold change. To identify how many significant genes had appreciable differences in fold change, both the unamplified and 10-ng data sets were independently filtered to identify significant genes (fold change > 2.0; P score < 0.001) and the union of these two sets taken. Open circles show the subset of these genes that had fold changes with a greater than 2-fold difference between protocols. (b) Comparison of fold changes from the 10-and 100-ng samples, shaded as in panel a. between fold changes, 47 genes fail the test (2.1%). Figure 2b shows the same comparison between 10 and 100 ng samples; 19 of 1441 genes (1.3%) are within 2-fold and 0 within 4-fold. Figure 3 shows the results of comparing the replicates produced with different protocols. Fold changes were computed between unamplified MCF7 and MCF10A and between MCF7 and unamplified MCF10A and compared as before. Unfortunately, 2042 out of 3241 (63%) probe sets showed greater than 2-fold difference in their fold changes. Worse, many probe sets appear to be up-regulated in one data set, but down in the other. Clearly, comparison between replicates generated with different protocols is dangerous.
If we consider that each protocol will introduce both systematic and random errors into the expression levels measured for each transcript, then if the systematic component is multiplicative when we compare replicates processed using the same protocol, the systematic error will disappear when the fold change is calculated (because fold change is calculated by dividing one expression level by the other). This may be why we see few discrepancies when we compare replicates produced using the same protocol, but many when we compare across protocols.
Distance from Probe Set to the 3′ End in Relation to Probe Set Expression Values
As we have seen, the GAPDH and β-actin 5′ to 3′ ratios are significantly greater in amplified samples than in unamplified samples, suggesting an increased 3′ bias in the amplified mRNA population. This is confirmed by looking at how the intensities of probes within a probe set vary according to their position. Figure 4 was generated (using the AffyRNAdeg function in BioConductor) by numbering each probe in a probe set according to its position from the 3′ end of the sequence. The mean intensities at every point were then calculated and plotted Figure 3 . Effect of using replicates generated by different protocols to generate fold changes. To investigate whether replicates processed using alternate protocols could be compared, fold changes were calculated between MCF7 and MCF10A samples, each set of replicates processed with different protocols. Crosses show fc MCF7:10ng:MCF10A:10μg plotted against fc MCF7:10μg:MCF10A:10ng . If the choice of protocol had no effect on fold change, this would produce a diagonal line. Once again, these data sets were filtered to identify significantly changing genes (fold change > 2; P score < 0.001) and the union of the two sets taken. Filled circles show significant genes with greater than 2-fold deviation in fold change between data sets. It can be seen that when replicates are processed using different protocols, this has a major influence on fold change.
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per array. There is a general drop off in intensity away from the 3′ end, and the effect is greater for amplified samples than unamplified samples. However, it can be seen that the starting amount of RNA before amplification does not have an impact on the magnitude of the effect because the slopes for all amplified samples have a similar gradient.
These plots, however, consider only the sequential ordering of the probes, rather than their actual position, and do so before normalization. Thus, there is 3′ bias, but it is not possible to deduce how much of an effect it will have on calculations of differential gene expression, which are carried out after normalization. Moreover, the fact that the curves from each protocol are parallel indicates that the differences are systematic, affecting all samples processed with the same protocol in the same way. Normalization is designed to deal with this sort of variation, and we can expect it to successfully correct for these sorts of errors.
To investigate the effects of positional bias after normalization, fold changes between the 10-μg samples were compared to those produced from the 10-ng samples by calculating for each probe set the absolute difference between them [i.e., abs(fc 10μg -fc 10ng )]. This was plotted against the probe set's distance from the 3′ end of its transcript (Figure 5a ). Distance was measured from the middle of each probe set, although similar results are obtained by using either the 5′-or 3′-most probes instead. Lines represent loess curves fitted to the data. If 3′ bias had a significant effect on the fold change determined for each gene, we would expect the deviation in fold change between each sample to increase with the 3′ distance. Figure 5a shows that after normalization, differences between the fold changes computed for the 10-μg samples and the 10-ng samples are not significantly correlated with probe set position. When replicate groups are swapped (fold changes computed between unamplified MCF7 and MCF10A and between MCF7 and unamplified MCF10A) and plotted against position as before, there is a detectable positional effect (Figure 5b ). These data demonstrate that although there is a drop off in probe intensity with distance from the 3′ end, and that the effect is greater with the amplified samples (as shown in Figure  4 ), this positional effect is consistent within a protocol, and the process of computing a fold change by dividing expression levels removes this bias effect from the data. Together, Figures 4 and 5 suggest that 3′ bias is a source of systematic variation, but that appropriate data analysis can have a significant effect in controlling it.
DISCUSSION
Here we have shown how differences between RNA preparation protocols can cause significant changes in the gene expression patterns measured by a microarray experiment, and that this makes direct comparison across protocols dangerous. However, what we have seen is that while chips prepared using different protocols cannot be effectively compared to one another, experiments can be, given the correct analytical treatment.
Particularly in the early days of microarray studies, it was not uncommon to find that chips clustered primarily according to the technician that performed the hybridizations, the production batch of the arrays or reagents, differences in laboratory protocols, or even the prevailing weather conditions (3, (23) (24) (25) (26) (27) . Numerous other studies have demonstrated that tissue heterogeneity, interpatient differences, and the inherent noise associated with real biological systems are also major sources of experimental variation (28) (29) (30) (31) . Efforts to standardize laboratories protocols, better array manufacturing, and overall good laboratory practice, coupled with an awareness of the issues, have all served to minimize the technical errors associated with microarray studies, and it is becoming apparent that in a well-executed experiment, the greatest source of variation is now typically due to biological differences rather than technical noise (31, 32) .
However, the need for such close standardization should raise some uncomfortable questions. Although careful conformance to well-defined protocols allows experimental variation and therefore disagreement between samples to be controlled; this improvement may simply be an illusion. By reducing the differences between the way samples are processed, random effects might be minimized, but as we have seen, this does nothing to deal with systematic errors. Standardization implies a choice between potential protocols; if two protocols yield different results, we must be able to decide in advance which protocol is correct.
Alternatively, we must accept that only calculations that side step systematic errors (such as fold change) are appropriate for analyzing microarray data. When we do this, we see that two different protocols, with all their inherent problems of 3′ bias and possible nonlinear amplification of transcripts, can be compared effectively. The removal of systematic errors in this way is desirable but has implications for comparisons that depend on the actual reported intensities, rather than the changes observed between different samples (clustering techniques, for example, using distance metrics that take into account the intensity of a gene expression profile, rather than simply its shape). In addition, we can see that the measured expression level of a transcript is influenced not only by effects such as dye and hybridization efficiencies, but also by the complexities of the amplification and the labeling protocols themselves.
Rather than deal with issues at the data analysis stage, it would also be possible to use a common reference pool of RNA to generate an expression pattern for each protocol. These can then be used to normalize between samples processed in different ways (perhaps by calculating fold change with respect to RNA TECHNOLOGIES the reference samples). This is similar to the approach taken in many twocolor microarray experiments. Finally, quality control may also play a part in determining whether arrays are directly comparable. When numerical metrics are available, quality control provides a set of descriptive statistics that could potentially be used to represent the distance between arrays and thus provide a well-defined predictor of comparability.
Given that the systematic errors introduced by different RNA preparation protocols are probably unavoidable and likely to be beyond the control of the biologist, data analysis techniques should be chosen with these effects in mind. The route from sample to spreadsheet is a complex one; we must learn to love our data for all that they have been through.
